BiomX reports Q2 net loss $6.0M, cash $15.2M; BX211 shows >40% wound reduction in Phase 2

BiomX Inc.

2025-Q2 EPS reported $0.50

Cash and restricted cash $15.2M at June 30, 2025; estimated to fund ops into Q1 2026.
Net loss $6.0M for Q2 2025 vs. income $4.5M in Q2 2024, driven by warrant fair value change.
BX211 Phase 2: >40% wound size reduction vs placebo in diabetic foot osteomyelitis; registrational study planning underway.
BX004 Phase 2b in CF successfully initiated dosing; topline results expected Q1 2026.
Nature Comm. publication: BX004 showed ~500-fold (2.7 log₁₀) bacterial reduction vs placebo with no resistance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.